Post-treatment effects of 0.1, 0.9 or 10 mg · ml−1 ofS-(+)-3-IBG or R-(−)-3-IBG on PWL, joint circumference and spontaneous pain rating score
| 0.1 mg · ml−1 | 0.9 mg · ml−1 | 10 mg · ml−1 | |
|---|---|---|---|
| S-(+)-3-IBG | |||
| PWL at 4 h (% baseline), A | 85 ± 3 | 73 ± 2 | 77 ± 3 |
| PWL after drug (% baseline), B | 86 ± 3 | 84* ± 2 | 98* ± 6 |
| B − A | 1 ± 3 | 11 ± 3 | 21 ± 6 |
| Score | 2.1 ± 0.3 | 0.6+ ± 0.2 | 0.2+ ± 0.2 |
| Circumference (% baseline) | 17 ± 1 | 18 ± 2 | 18 ± 4 |
| R-(−)-3-IBG | |||
| PWL at 4 h (% baseline), A | 88 ± 4 | 72 ± 2 | 82 ± 5 |
| PWL after drug (% of baseline), B | 82 ± 2 | 82* ± 3 | 97* ± 5 |
| B − A | −6 ± 3 | 10 ± 0.5 | 15 ± 0.5 |
| Score | 2.5 ± 0.4 | 0.1+ ± 0.1 | 0+ ± 0.3 |
| Circumference (% baseline) | 15 ± 3 | 14 ± 1 | 19 ± 1 |
Values shown are: PWL after inflammation (4 h), after the drug (5.5 h after inflammation) and the difference between these two values; spontaneous pain rating score and joint circumference after drug treatment. * P < .05 significantly different from 4-h value within the same treatment group (paired t-test).+ P < .05 significantly different from 4-h value within the same treatment group (Wilcoxon test). Values are means (n = 6).